Publications by authors named "J L Shinn"

Objective:  To determine the readability and quality of both English and Spanish Web sites for the topic of hearing aids.

Study Design:  Cross-sectional Web site analysis.

Setting:  Various online search engines.

View Article and Find Full Text PDF

Background/aims: Statins are common lipid-lowering agents used in dyslipidemia. However, they increase serum creatinine phosphokinase (CPK) levels. Currently, there are no studies on the effect of thyroid-stimulating hormone (TSH) levels on CPK levels after statin administration.

View Article and Find Full Text PDF

Introduction: The tumor microenvironment (TME) has attracted considerable attention as a potential therapeutic target for cancer. High levels of reactive oxygen species (ROS) in the TME may act as a stimulus for drug release. In this study, we have developed ROS-responsive hyaluronic acid-bilirubin nanoparticles (HABN) loaded with doxorubicin (DOX@HABN) for the specific delivery and release of DOX in tumor tissue.

View Article and Find Full Text PDF

Objective: Telehealth evaluation of hearing is rapidly evolving; however, the lack of consensus on the most accurate remote hearing test application has made hearing evaluation complicated. The objective of this study was to evaluate the correlation between the pure tone audiometry results obtained from app-based hearing testing programs and a traditional audiogram.

Methods: A prospective within-subject and between-subject study design was used to correlate audiogram results between app-based hearing programs and a traditional audiogram.

View Article and Find Full Text PDF
Article Synopsis
  • New biologics and small molecule treatments for moderate-to-severe ulcerative colitis, including mirizikizumab and upadacitinib, have been approved, but there are no direct comparison studies available to guide their use.
  • Clinical trials show mixed results: ozanimod, etrasimod, and mirizikizumab have lower remission rates in patients with prior biologic experience, while upadacitinib performs similarly; however, it carries the highest risk of adverse events.
  • Experts suggest using ozanimod or etrasimod for mild-to-moderate cases and recommending mirizikizumab for moderate-to-severe cases, with a careful consideration of patient history when choosing between upad
View Article and Find Full Text PDF